Biotin Anti-Human HLA-DR (L243) Mouse IgG2a Recombinant Antibody
HLA-DR Recombinant Antibody for FC
Host / Isotype
Mouse / IgG2a
Reactivity
human
Applications
FC
Conjugate
Biotin
CloneNo.
L243
Cat no : Biotin-65560
Synonyms
Validation Data Gallery
Tested Applications
Positive FC detected in | human PBMCs |
Recommended dilution
Application | Dilution |
---|---|
This reagent has been tested for flow cytometric analysis. It is recommended that this reagent should be titrated in each testing system to obtain optimal results. | |
Sample-dependent, Check data in validation data gallery. |
Product Information
Biotin-65560 targets HLA-DR in FC applications and shows reactivity with human samples.
Tested Reactivity | human |
Host / Isotype | Mouse / IgG2a |
Class | Recombinant |
Type | Antibody |
Immunogen | Human lymphoblastoid B-cell line RPMI 8866 相同性解析による交差性が予測される生物種 |
Full Name | major histocompatibility complex, class II, DR alpha |
Calculated molecular weight | 254 aa, 29 kDa |
GenBank accession number | BC032350 |
Gene symbol | HLA-DRA |
Gene ID (NCBI) | 3122 |
RRID | AB_3672372 |
Conjugate | Biotin |
Form | Liquid |
Purification Method | Protein A purification |
Storage Buffer | PBS with 0.09% sodium azide. |
Storage Conditions | Store at 2-8°C. Avoid exposure to light. Stable for one year after shipment. |
Background Information
HLA-DR is a member of MHC class II moleculesencoded by the human leukocyte antigen complex on the region 6p21.31 of chromosome 6. HLA-DR is composed of two non-covalently associated transmembrane glycoproteins (the α and β chains), and is primarily expressed on B lymphocytes, monocytes, dendritic cells and thymic epithelial cells (PMID: 33125816). HLA-DR participate in the antigen presentation to CD4+ or CD8+ T cells and is postulated as a general biomarker of sepsis-induced immunosuppression (PMID: 28199206, 32421903).
Protocols
Product Specific Protocols | |
---|---|
FC protocol for Biotin HLA-DR antibody Biotin-65560 | Download protocol |
Standard Protocols | |
---|---|
Click here to view our Standard Protocols |